Evidence map›Paper›PMID 37013423›Full record

ArticleTherapeutic advances in respiratory disease

Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study.

Edward C Portillo, Michael Pollack, Inyoung Lee, Kainan Sun, Xiaohui Zhao, Lisa Kruse, Norbert Feigler, Sushma Patel, Aimee M Near

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Observational
  5. Observational
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Edward C PortilloSchool of Pharmacy, University of Wisconsin, Madison, WI, USA.
Michael PollackUS Medical, BioPharmaceuticals, AstraZeneca, 1800 Concord Pike, Wilmington, DE 19850, USA.
Inyoung LeeIQVIA, Durham, NC, USA.
Kainan SunIQVIA, Durham, NC, USA.
Xiaohui ZhaoIQVIA, Durham, NC, USA.ORCID 0000-0001-8757-6587
Lisa KruseUS Medical, BioPharmaceuticals, AstraZeneca, Wilmington, DE, USA.
Norbert FeiglerUS Medical, BioPharmaceuticals, AstraZeneca, Wilmington, DE, USA.
Sushma PatelUS Medical, BioPharmaceuticals, AstraZeneca, Wilmington, DE, USA.
Aimee M NearIQVIA, Durham, NC, USA.
AstraZeneca (United States) · USIQVIA (United States) · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA twice-daily single inhaler triple therapy consisting of budesonide/glycopyrrolate/formoterol fumarate (BGF) was approved by the US Food and Drug Administration (FDA) in July 2020 as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The objective of this AURA study is to describe patient characteristics, exacerbation and treatment history, and healthcare resource utilization (HCRU) before BGF initiation to better inform treatment decisions for prescribers.

methodsThis retrospective cohort study leveraged data of all payer types from IQVIA's Longitudinal Prescription Data (LRx) linked to Medical Data (Dx). Patients with COPD who had ⩾1 LRx claim for BGF between 1 October 2020 and 30 September 2021 were included. The date of first BGF claim was the index date. Patient demographic and clinical characteristics, history of COPD exacerbation or related event, treatment history, and HCRU were assessed during the 12 months before index (baseline).

resultsWe identified 30,339 patients with COPD initiating BGF (mean age: 68.2 years; 57.1% female; 67.6% Medicare). Unspecified COPD (J44.9; 74.0%) was the most commonly coded COPD phenotype. The most prevalent respiratory conditions/symptoms were dyspnea (50.8%), lower respiratory tract infection (25.3%), and sleep apnea (19.0%). Uncomplicated hypertension (58.8%), dyslipidemia (43.9%), cardiovascular disease (41.4%), and heart failure (19.9%) were the most prevalent nonrespiratory conditions. During the 12-month baseline, 57.9% of patients had evidence of a COPD exacerbation or related event, and 14.9% had ⩾1 COPD-related emergency department (ED) visit; 21.0% of patients had evidence of prior triple therapy use, while 54.3% had ⩾1 oral corticosteroid (OCS) fill. Among OCS users, 29.9% had cumulative exposures >1000 mg [median [Q1-Q3] exposure: 520 (260-1183) mg].

conclusionThis real-world data analysis indicates that BGF is being initiated in patients with COPD experiencing symptoms and exacerbations despite current therapy, and among patients who have various chronic comorbidities, most often cardiopulmonary-related.

Indexed as

Bronchodilator AgentsPulmonary Disease, Chronic ObstructiveAdministration, InhalationAgedBudesonideDrug CombinationsFemaleFormoterol FumarateGlycopyrrolateHumansMaleMedicareMetered Dose InhalersRetrospective StudiesUnited StatesBronchodilator AgentsBudesonideDrug CombinationsFormoterol FumarateGlycopyrrolatebudesonide/glycopyrrolate/formoterolchronic obstructive pulmonary diseaseexacerbationsreal-world datasingle-inhaler triple therapy

Identifiers

PMID37013423
PMCPMC10074608
OpenAlexW4362523809

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.